FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment

Supplemental Biologics License Application would convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) to a full approval for patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Source link
#FDA #Grants #Priority #Review #Pfizer #Genmab039s #Tivdak #Cervical #Cancer #Treatment